Search
Human Rho(D) immune globulin
go.drugbank.com/drugs/DB11597ApprovedIt was approved by FDA as treatment for suppression of rhesus (Rh) isoimmunization or chronic immune thrombocytopenic purpura (ITP) in adults. … Human Rho(D) immune globulin is a medicine given by intramuscular or intravenous injection that is used to prevent the immunological condition known as Rh disease (or hemolytic disease of newborn).
Categories: Antiinfectives for Systemic UseEntrectinib
go.drugbank.com/drugs/DB11986ApprovedInvestigational[L8081] It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors. … [L8207] Entrectinib's approved use is meant as a last line of therapy due to its accelerated approval based on early trial data.
Tremelimumab
go.drugbank.com/drugs/DB11771ApprovedInvestigational[A253717, A253722] After receiving an EMA Committee for Medicinal Products for Human Use (CHMP) recommendation in December 2022, tremelimumab was approved for combined use with [durvalumab].[L46188] … [A253717] By binding to CTLA-4, tremelimumab enhances T cell-mediated killing of tumours and reduces tumour growth.
Vanoxerine
go.drugbank.com/drugs/DB03701Investigational[A248555] Vanoxerine is an investigational drug and has not been approved for therapeutic use. … Although several studies have suggested that the profile of vanoxerine is safer than that of cocaine,[A19824,A248550] other studies have found that vanoxerine has at least moderate potential to be abused by
Daclatasvir
go.drugbank.com/drugs/DB09102ApprovedInvestigationalWithdrawnDaclatasvir was FDA-approved in July 2015 for use with [DB08934] (Sovaldi) with or without [DB00811] to treat HCV genotype 1 and 3 infections. … It exerts its antiviral action by preventing RNA replication and virion assembly via binding to NS5A, a nonstructural phosphoprotein encoded by HCV.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseNeon
go.drugbank.com/drugs/DB11589ApprovedIt is the fifth most abundant chemical element in the universe by mass but a rare element on Earth.
Orforglipron
go.drugbank.com/drugs/DB18964ApprovedInvestigational[L56123] On April 1, 2026, the US FDA granted approval to orforglipron for use alongside diet and exercise to aid in weight reduction in certain patient populations.
Pegunigalsidase alfa
go.drugbank.com/drugs/DB14992ApprovedInvestigationalPegunigalsidase alfa (PRX-102) is a recombinant form of human α-galactosidase-A indicated for long-term enzyme replacement therapy in patients with Fabry disease, a rare genetic disorder characterized by
Bacillus calmette-guerin substrain russian BCG-I live antigen
go.drugbank.com/drugs/DB16648ApprovedInvestigational[L32734] It is to be marketed by Verity Pharmaceuticals, under the trade name VERITY-BCG, and manufactured by the Serum Institute of India. … It was developed to alleviate Canada's multi-year shortage of BCG vaccine, and is expected to be available by mid-2021.[L32734]
Loracarbef
go.drugbank.com/drugs/DB00447ApprovedWithdrawnLoracarbef is a carbacephem antibiotic sometimes grouped together with the second-generation cephalosporin antibiotics. It is marketed under the trade name Lorabid.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use